London
· Delayed Price · Currency is GBP · Price in GBXAllergy Therapeutics Statistics
Total Valuation
Allergy Therapeutics has a market cap or net worth of GBP 204.96 million. The enterprise value is 201.28 million.
| Market Cap | 204.96M |
| Enterprise Value | 201.28M |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Allergy Therapeutics has 4.77 billion shares outstanding. The number of shares has increased by 160.33% in one year.
| Shares Outstanding | 4.77B |
| Shares Change (YoY) | +160.33% |
| Shares Change (QoQ) | +300.56% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 2.74% |
| Float | 225.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| PB Ratio | 7.75 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.01 |
| EV / Sales | 3.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.52 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 37.22.
| Current Ratio | 1.40 |
| Quick Ratio | 0.93 |
| Debt / Equity | 37.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -7.90 |
Financial Efficiency
Return on equity (ROE) is -155.90% and return on invested capital (ROIC) is -58.18%.
| Return on Equity (ROE) | -155.90% |
| Return on Assets (ROA) | -34.76% |
| Return on Capital (ROIC) | -58.18% |
| Revenue Per Employee | 87,023 |
| Profits Per Employee | -82,052 |
| Employee Count | 612 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +224.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +224.03% |
| 50-Day Moving Average | 4.79 |
| 200-Day Moving Average | 3.33 |
| Relative Strength Index (RSI) | 42.37 |
| Average Volume (20 Days) | 304,015 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Allergy Therapeutics had revenue of GBP 53.26 million and -50.22 million in losses. Loss per share was -0.03.
| Revenue | 53.26M |
| Gross Profit | 27.98M |
| Operating Income | -39.12M |
| Pretax Income | -48.48M |
| Net Income | -50.22M |
| EBITDA | -37.00M |
| EBIT | -39.12M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 13.52 million in cash and 9.85 million in debt, giving a net cash position of 3.67 million or 0.00 per share.
| Cash & Cash Equivalents | 13.52M |
| Total Debt | 9.85M |
| Net Cash | 3.67M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 26.46M |
| Book Value Per Share | 0.01 |
| Working Capital | 10.08M |
Cash Flow
In the last 12 months, operating cash flow was -32.20 million and capital expenditures -4.28 million, giving a free cash flow of -36.48 million.
| Operating Cash Flow | -32.20M |
| Capital Expenditures | -4.28M |
| Free Cash Flow | -36.48M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 52.54%, with operating and profit margins of -73.45% and -94.29%.
| Gross Margin | 52.54% |
| Operating Margin | -73.45% |
| Pretax Margin | -91.03% |
| Profit Margin | -94.29% |
| EBITDA Margin | -69.47% |
| EBIT Margin | -73.45% |
| FCF Margin | -68.50% |
Dividends & Yields
Allergy Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -160.33% |
| Shareholder Yield | -160.33% |
| Earnings Yield | -68.89% |
| FCF Yield | -17.80% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |